(Q35537846)

8 August 2017

1 reference

title

Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis (English)

1 reference

8 August 2017

0 references

1 reference

1 reference

2

David Figgitt

1 reference

8 August 2017

Gillian Keating

1

1 reference

8 August 2017

publication date

1 January 2003

1 reference

8 August 2017

1 reference

8 August 2017

volume

63

1 reference

8 August 2017

issue

20

1 reference

8 August 2017

page(s)

2235-2263

1 reference

Antifungal drug resistance

8 August 2017

cites work

1 reference

12 December 2020

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

1 reference

12 December 2020

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

1 reference

12 December 2020

Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice

1 reference

12 December 2020

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients

1 reference

12 December 2020

British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections

1 reference

12 December 2020

Glucan synthase inhibitors as antifungal agents

1 reference

12 December 2020

Antifungal susceptibility testing: practical aspects and current challenges

1 reference

12 December 2020

Caspofungin acetate for treatment of invasive fungal infections

1 reference

12 December 2020

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

1 reference

12 December 2020

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

12 December 2020

Voriconazole: in the treatment of invasive aspergillosis

1 reference

12 December 2020

1 reference

12 December 2020

In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance

1 reference

12 December 2020

Treatment of murine disseminated candidiasis with L-743,872

1 reference

12 December 2020

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

12 December 2020

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

12 December 2020

Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis

1 reference

12 December 2020

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

12 December 2020

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer

1 reference

12 December 2020

Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit

1 reference

12 December 2020

Combination therapy with caspofungin and amphotericin B lipid complex.

1 reference

12 December 2020

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

12 December 2020

Invasive aspergillosis in 2002: an update

1 reference

12 December 2020

Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients.

1 reference

12 December 2020

A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America

1 reference

12 December 2020

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

1 reference

12 December 2020

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

1 reference

12 December 2020

Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species

1 reference

12 December 2020

Invasive Aspergillus infections in hematologic malignancy patients

1 reference

12 December 2020

Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates

1 reference

12 December 2020

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

1 reference

12 December 2020

In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species

1 reference

12 December 2020

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

1 reference

12 December 2020

In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds

1 reference

12 December 2020

Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods

1 reference

12 December 2020

Antifungal drug resistance of pathogenic fungi.

1 reference

12 December 2020

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

12 December 2020

In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

1 reference

12 December 2020

In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points

1 reference

12 December 2020

New antifungal agents-treatment standards are beginning to grow old.

1 reference

12 December 2020

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole

1 reference

12 December 2020

Invasive oesophageal candidiasis: current and developing treatment options

1 reference

12 December 2020

Has antifungal susceptibility testing come of age?

1 reference

12 December 2020

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

1 reference

12 December 2020

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

12 December 2020

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

1 reference

12 December 2020

Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species

1 reference

12 December 2020

Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

1 reference

12 December 2020

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

12 December 2020

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 reference

12 December 2020

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

12 December 2020

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

1 reference

12 December 2020

1 reference

12 December 2020

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

12 December 2020

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

12 December 2020

In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions

1 reference

12 December 2020

Optimal use of existing and new antifungal drugs

1 reference

12 December 2020

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

1 reference

12 December 2020

Deeply invasive candidiasis

1 reference

12 December 2020

Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine

1 reference

12 December 2020

Caspofungin: an echinocandin antifungal agent

1 reference

12 December 2020

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

12 December 2020

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

12 December 2020

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

1 reference

12 December 2020

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

12 December 2020

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

1 reference

12 December 2020

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

1 reference

12 December 2020

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

1 reference

12 December 2020

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

12 December 2020

Antifungal resistance among Candida species

1 reference

12 December 2020

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

1 reference

12 December 2020

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

1 reference

12 December 2020

Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin

1 reference

12 December 2020

Echinocandins--an advance in the primary treatment of invasive candidiasis

1 reference

12 December 2020

Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

1 reference

12 December 2020

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

12 December 2020

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

12 December 2020

10.2165/00003495-200363200-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

8 August 2017

1046640133

0 references

1 reference